Pharmaceutical Quality and Purity Analysis

Core Idea

Pharmaceutical analysis determines active pharmaceutical ingredient content, impurity profiles, and degradation products in drug substances and finished products. Methods must comply with pharmacopeial standards and regulatory requirements for stability and quality assurance.

Explainer

From your study of HPLC, you know how to separate and quantify components in a mixture using liquid chromatography. From method validation, you understand how to prove that an analytical method performs reliably within defined specifications. Pharmaceutical quality analysis is where these skills converge on one of the highest-stakes applications in analytical chemistry: ensuring that every dose of medication a patient takes contains the right amount of the right compound, with impurities controlled to levels that are safe for human consumption.

The central analytical task is assay — determining the content of the active pharmaceutical ingredient (API) in a drug product. A tablet labeled as containing 500 mg of acetaminophen must actually contain between 475 and 525 mg (typically 95–105% of label claim) when tested by the official pharmacopeial method. HPLC with UV detection is the workhorse technique, and the methods are defined in extraordinary detail by pharmacopeias such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These are not guidelines — they are legally enforceable standards. When a USP monograph specifies a C18 column, a particular mobile phase composition, and a detection wavelength, a quality control laboratory must either use that method exactly or demonstrate equivalence through formal validation.

Equally important is impurity profiling — identifying and quantifying all substances in a drug product that are not the intended API. Impurities fall into several categories: process-related impurities (unreacted starting materials, synthetic intermediates, catalysts, and residual solvents from manufacturing), degradation products (compounds formed by chemical breakdown of the API during storage due to heat, light, moisture, or oxidation), and elemental impurities (heavy metals from equipment or raw materials). Regulatory guidelines, particularly ICH Q3A/Q3B, set reporting, identification, and qualification thresholds based on the daily dose of the drug. For a drug taken at 2 g/day, any impurity above 0.05% must be reported, above 0.1% must be structurally identified, and above 0.15% must be qualified for safety. These are remarkably low levels, and achieving the chromatographic resolution and detection sensitivity to meet them is a significant analytical challenge.

Stability testing ties assay and impurity analysis together over time. Regulatory authorities require that drug products be tested under defined storage conditions — 25°C/60% relative humidity for long-term studies, 40°C/75% RH for accelerated studies — at specified time points throughout the product's shelf life. The goal is to demonstrate that the API content remains within specification and that impurity levels do not exceed qualified limits over the labeled storage period. A failing stability result does not just affect a single batch — it can trigger product recalls, shorten approved shelf lives, and require reformulation. For the analytical chemist in a pharmaceutical quality control laboratory, every chromatographic run carries this weight: the results determine whether medicine reaches patients or gets destroyed.